Pfizer BenaMist Launch Delayed By Manufacturing Issues
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Consumer Healthcare's launch of its BenaMist Allergy Prevention Nasal Spray is being delayed due to production problems faced by contract manufacturer Alpharma, Pfizer said
You may also be interested in...
Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy
Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets
Alpharma
Company will ship generic Cromolyn Sodium Nasal Solution USP to several major drugstores in the first half of August, firm says. Alpharma received final approval of ANDA 74-800 for its Nasalcrom equivalent July 26 and is second private labeler to receive FDA clearance; Bausch & Lomb's generic cromolyn sodium was approved in early July (1"The Tan Sheet" July 9, p. 28). Pharmacia's Nasalcrom lost marketing exclusivity July 3, 2000 after receiving six months of pediatric exclusivity
Benadryl Driving Impairment Study Findings "Suspect" - W-L
Recent study results suggesting OTC cold/allergy remedy Benadryl impairs driving abilities more than alcohol are "suspect" and the study design "is seriously flawed," Warner-Lambert stated.